05.05.26 -- FDA Letters Made Public Are Creating New Risks

Suspension‑adapted HEK293 cell lines support scalable, cost‑efficient AAV and LVV production with strong yields and regulatory confidence.

Comparing plasmid DNA to enzymatically produced DNA shows how enzymatic methods cut manufacturing costs, speed production, and boost efficiency for large‑scale AAV gene therapy.

Uncover how plant-based peptones support E. coli growth, plasmid yield, and controlled induction, offering a sustainable, animal-free alternative for biopharmaceutical cell culture.

Advanced therapies need bioanalysis partners built for complexity, not scale. CGT expertise, specialized platforms, and flexible timelines ensure dosing and safety data traditional CROs can’t support.

Discover how an autologous CAR-T platform is addressing challenges in cell therapy manufacturing. A three-day process shortens cycles, improves T-cell potency and durability, and reduces costs.

At Meeting on the Mesa 2025, we highlight in-house plasmid manufacturing, expanded commercialization development, and cost reduction in gene therapy manufacturing.

In times of uncertainty, collaboration becomes a strategic advantage. Explore how leading organizations can leverage collective expertise to navigate complexity, drive innovation, and build resilience.

Review the potential of AAV-mediated gene therapy as a platform approach to treat multiple genetic neurological diseases, and explore suggestions to streamline translational studies and reduce costs.

When it comes to furthering AAV's potential in the wider biopharmaceutical pipeline, partnering with a CDMO that can foment an optimal analytical and manufacturing strategy is crucial.

Explore insights into an AAV manufacturing platform designed to achieve short timelines and cost-effective scalability for producing clinical trial and commercial material in bioreactors up to 2000 L.

Uncover the elements of a complex process, prone to misconceptions and pitfalls, to find the “right human tissue” that will yield the desired cell quality and quantity and pass BLA approval.

Automated, closed cryo‑processing of leukapheresis preserves cell quality and functionality, enabling flexible, reproducible starting material for both autologous and allogeneic CAR‑T manufacturing.

As the field evolves, the strategies developers choose may prove just as influential as the therapies themselves in determining how quickly innovation reaches patients.